Source: International Congress 2014 – ILDs 1
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
H. Iwamoto, Y. Horimasu, T. Nakashima, S. Ohshimo, N. Ishikawa, K. Fujitaka, Y. Haruta, H. Murai, N. Hattori, W. Mazur, N. Kohno (Hiroshima, Japan; Helsinki, Finland). Decreased circulatory receptor for advanced glycation end-products is associated with poorer survival in patients with idiopathic pulmonary fibrosis. Eur Respir J 2014; 44: Suppl. 58, 741

Member's Comments

No comment yet.

Related content which might interest you: Comparison of physiological impairment in ILD patients with and without diagnostic IPF features Source: International Congress 2014 – ILDs 4 Year: 2014 MMP7-degraded elastin is elevated in serum of patients with idiopathic pulmonary fibrosis Source: International Congress 2014 – Basic and translational research in lung cancer and non-neoplastic pulmonary diseases Year: 2014 Surfactant protein B proforms as potential new biomarkers for idiopathic pulmonary fibrosis Source: International Congress 2014 – ILDs 2 Year: 2014 Predictors of efficacy of pirfenidone in idiopathic pulmonary fibrosis Source: International Congress 2014 – ILDs 4 Year: 2014 Idiopathic pulmonary fibrosis is associated with a preferential alteration of kCO rather than of DLCO Source: International Congress 2014 – ILDs 6 Year: 2014 Angiopoietin-2 gene polymorphism as prognostic factor in caucasians with idiopathic pulmonary fibrosis Source: International Congress 2014 – ILDs 1 Year: 2014 Prognostic influence of comorbidities in idiopathic pulmonary fibrosis (IPF) Source: International Congress 2014 – ILDs 2 Year: 2014 Role of midkine in idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view Year: 2013 Assessment of nutritional status in patients with idiopathic pulmonary fibrosis Source: International Congress 2016 – Long-term oxygen therapy, noninvasive ventilation, and other clinical variables in chronic lung diseases Year: 2016 Assessment of telomere length in the combined pulmonary fibrosis and emphysema syndrome Source: International Congress 2014 – ILDs: diagnostic and prognostic investigations Year: 2014 Club cell secretory protein-CC16 is increased in idiopathic pulmonary fibrosis Source: International Congress 2016 – ILD pathogenesis Year: 2016 Platelet activation indices in patients with Idiopathic Pulmonary Fibrosis Source: International Congress 2014 – ILDs 5 Year: 2014 Safety and efficacy of pirfenidone in severe idiopathic pulmonary fibrosis Source: International Congress 2014 – ILDs 3 Year: 2014 Transient elastography detection of early liver fibrosis in idiopathic pulmonary fibrosis patients Source: International Congress 2014 – ILDs 2 Year: 2014 Neutrophil elastase degraded elastin is elevated in serum of idiopathic pulmonary fibrosis Source: International Congress 2014 – New and old players in fibrotic lung disease Year: 2014 Prognostic significance of selected biomarkers in idiopathic pulmonary fibrosis, sarcoidosis, and chronic pulmonary obstructive disease Source: International Congress 2014 – Sarcoidosis Year: 2014 Increased levels of oxidative stress markers in patients with idiopathic pulmonary fibrosis Source: International Congress 2016 – Common mechanisms in lung development and fibrosis Year: 2016 Long term efficacy of pirfenidone therapy in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2014 – ILDs 3 Year: 2014 Proportion of idiopathic pulmonary fibrosis among interstitial lung disease in a tertiary care center and its response to treatment Source: International Congress 2014 – ILDs 5 Year: 2014 Long-term survival analysis: Pirfenidone compared to standard care for the treatment of patients with idiopathic pulmonary fibrosis Source: International Congress 2014 – Clinical trials in IPF Year: 2014